Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJiayuan Sun
About this trial
The study aims to compare the efficacy and safety of transthoracic cryoablation to transbronchial cryoablation in the treatment of early-stage peripheral lung cancer.
Eligibility criteria
Qualifiers
Age older than 18 years.
Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary).
The target lesion was evaluated to be feasible for both CT and bronchoscopy-guided ablation.
Patients who are not suitable for surgery or refuse surgery, agree to undergo initial ablation therapy and sign informed consent form.
Disqualifiers
Patients with platelets <70×109/L, severe bleeding tendency and coagulation dysfunction that cannot be corrected in a short term.
Patients with severe pulmonary fibrosis and pulmonary arterial hypertension.
Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever >38.5°C.
Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in a short term.
Trial design
Treatments tested in this trial
- Transthoracic cryoablation
- Transbronchial cryoablation
Treatment groups
110 Participants
are divided into 2 treatment groupsSponsors and collaborators
Jiayuan Sun
Lead sponsor
Shanghai Chest Hospital
Sponsor institution
Source ClinicalTrials.gov